Haemonetics (NYSE:HAE) Stock Price Target Raised at Barrington Research

Haemonetics (NYSE:HAE) had its price target boosted by stock analysts at Barrington Research from $140.00 to $145.00 in a research note issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research‘s target price points to a potential upside of 21.55% from the company’s current price.

HAE has been the topic of a number of other research reports. Mizuho set a $165.00 price target on Haemonetics in a research note on Thursday. Citigroup lifted their price objective on Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Robert W. Baird upped their target price on Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a research note on Friday, August 21st. Raymond James Financial increased their target price on Haemonetics from $105.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, September 3rd. Finally, JPMorgan Chase & Co. raised their price target on Haemonetics from $62.00 to $86.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $114.67.

Haemonetics Price Performance

Shares of NYSE HAE traded down $4.82 during midday trading on Friday, hitting $119.29. The company had a trading volume of 455,632 shares, compared to its average volume of 809,977. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. Haemonetics has a twelve month low of $51.00 and a twelve month high of $132.00. The business has a 50-day simple moving average of $111.18 and a two-hundred day simple moving average of $79.80. The firm has a market capitalization of $5.43 billion, a price-to-earnings ratio of 58.43, a price-to-earnings-growth ratio of 2.55 and a beta of 0.63.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The firm had revenue of $357.76 million for the quarter, compared to analysts’ expectations of $345.15 million. During the same period in the prior year, the company earned $1.27 EPS. The firm’s revenue was up 9.4% on a year-over-year basis. Equities research analysts anticipate that Haemonetics will post 5.29 earnings per share for the current year.

Institutional Trading of Haemonetics

Several institutional investors and hedge funds have recently bought and sold shares of HAE. Brighton Jones LLC bought a new position in Haemonetics in the third quarter worth $264,000. May Hill Capital LLC raised its stake in shares of Haemonetics by 12.1% in the 3rd quarter. May Hill Capital LLC now owns 25,093 shares of the medical instruments supplier’s stock valued at $2,642,000 after buying an additional 2,705 shares in the last quarter. Vise Technologies Inc. acquired a new position in shares of Haemonetics in the 3rd quarter valued at $613,000. VIRGINIA RETIREMENT SYSTEMS ET Al lifted its holdings in shares of Haemonetics by 178.6% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 11,700 shares of the medical instruments supplier’s stock worth $1,232,000 after acquiring an additional 7,500 shares during the period. Finally, VestGen Advisors LLC bought a new position in shares of Haemonetics during the 3rd quarter worth about $2,901,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Fiscal Q2 revenue was $357.8 million, above the roughly $345 million consensus and up 9.4% year over year. Adjusted earnings were $1.35 per share, topping the $1.29 estimate and rising from $1.27 a year earlier. Haemonetics Q2 results and guidance
• Positive Sentiment: Management raised its FY2027 revenue and organic-growth outlook, projecting organic growth of 6%–9%. That signals confidence in continued demand and execution. FY2027 growth outlook and CSL Persona PLUS rollout
• Positive Sentiment: BTIG raised its price target to $142 from $130 and maintained a Buy rating, adding a favorable analyst signal. BTIG analyst ratings
• Neutral Sentiment: Haemonetics plans to scale the CSL Persona PLUS rollout through calendar 2027. This could support future growth, though the rollout’s pace and execution remain factors to monitor. CSL Persona PLUS rollout
• Negative Sentiment: The earnings-call coverage highlighted tradeoffs between growth and margins. Investors may be focused on the cost or profitability implications of pursuing growth and scaling the rollout, despite the quarter’s beat. Earnings call growth and margin tradeoffs

About Haemonetics

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.